Clinical trials: Malignant Neoplasm of Liver
Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8
Intravital Microscopy in Human Solid Tumors
This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated…
- Conditions
- Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma
- Trial name
- NCT03823144
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Mayo Clinic
Hepatic Carcinoma Malignant Primary Non-Resectable
Liquid Biopsy in Hepatocellular Carcinoma
Circulating tumor DNA (ctDNA) carrying tumor-specific sequence alterations has been found in the cell-free fraction of blood. Hepatocellular carcinoma (HCC) specimens are difficult to obtain, and noninvasive methods are required…
- Trial name
- HCCGenePanel (NCT04111029)
- Testing
- Cell Free DNA
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cancer, Metastatic Cancer
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Trans arterial chemoembolization (TACE) has emerged as a treatment option for chemotherapy-refractory diseases in Liver metastases.
- Conditions
- Cancer, Metastatic Cancer, Liver Metastases
- Trial name
- NCT06311851
- Testing
- Bevacizumab
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Pardis Noor Medical Imaging and Cancer Center
Primary Malignant Liver Neoplasm
Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors
This clinical trial studies how well yttrium-90 (Y90) glass microspheres positron emission tomography (PET)/computed tomography (CT) works in imaging patients with liver tumors .
- Trial name
- NCT03109262
- Testing
- Computed Tomography (CT), Positron Emission Tomography (PET), 90-Yttrium (Y-90) Glass Microspheres
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Stanford University
Esophagus Cancer, Bladder Cancer
The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Phase Ia: single-dose escalation study: accelerated titration combined with traditional "3+3" dose. Sample size is correlated with the DLT occurring in each dose group.
- Conditions
- Esophagus Cancer, Bladder Cancer, Liver Cancer, Ovarian Cancer
- Trial name
- NCT05829057
- Testing
- Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal Antibody
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Zhejiang University
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Adult Liver Carcinoma, Breast Carcinoma
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
This randomized pilot clinical trial studies body warming in improving blood flow and oxygen delivery to tumors in patients with cancer. Heating tumor cells to several degrees above normal body temperature may kill tumor cells.
- Conditions
- Adult Liver Carcinoma, Breast Carcinoma, Colon Carcinoma, Kidney Neoplasm
- Trial name
- NCT01896778
- Testing
- Hyperthermia Treatment, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Hepatocellular Carcinoma, Cholangiocarcinoma
Liver Embolization Approaches for Tumor Management
The goal of this evaluate short, medium and long term outcome of the different embolization techniques in patients with primary and secondary hepatic tumors.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Metastatic Colon Cancer, Metastatic Cancer
- Trial name
- LEATUM (NCT05714124)
- Testing
- Embolization
- Where
- Italy
- Volunteers
- 580 people
- Sponsor
- IRCCS San Raffaele
Liver Neoplasm
Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors
Microwave ablation is a minimally invasive technique whose planning relies on manufacturer tables derived from ex vivo models that do not account for patient or tumor-specific factors.
- Trial name
- MICRO-VAR (NCT07413640)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Central Hospital, Nancy, France
Cancer, Abdominal Cancer
Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
It is a non-randomized pilot study.The allocation will be determined by patients or their immediate family members who were cooperative with physician's interpretations on the disease progression and updated information of…
- Conditions
- Cancer, Abdominal Cancer, Pelvic Cancer, Metastatic Cancer
- Trial name
- NCT03757858
- Testing
- Thermotron RF-8, Adoptive cellular Immunotherapy, Anti-PD-1 antibody
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Capital Medical University
Advanced Malignant Solid Tumor, Solid Tumor Cancer
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012 are in treating cancer.
- Trial name
- NCT07337525
- Testing
- PLT012
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pilatus Biosciences Inc
Hepatoblastoma, Hepatocellular Carcinoma (HCC)
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are…
- Conditions
- Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer
- Trial name
- ARYA-2 (NCT04634357)
- Testing
- ET140203 T Cells
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Eureka Therapeutics Inc.
Liver Malignant Tumors
Histotripsy for Ablation of Liver Tumours in Asia
The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease.
- Trial name
- HALT (NCT07428356)
- Testing
- Histotripsy using HistoSonics Edison™ System
- Where
- 3 sites in Singapore
- Volunteers
- 40 people
- Sponsor
- National Cancer Centre, Singapore
HCC, Metastasis
Monopolar Radiofrequency Ablation Using a Dual Switching System and a Separable Clustered Electrode (Octopus®)
Increasing ablative zone is an essential part to improve technical success and long term outcome in patient treated with radiofrequency ablation (RFA).
- Trial name
- NCT02675881
- Testing
- DSM, separable clustered electrode
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Fallopian Tube Cancer, Metastatic Cancer
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or…
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005645
- Testing
- ILX-295501
- Where
- 8 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Hepatocellular Cancer, AFP Expressing Tumors
AFPᶜ³³²T in Advanced HCC
This first time in human study is intended for men and women between 18 and 75 years of age who have advanced liver cancer which has grown or returned after being treated or another AFP expressing tumor.
- Trial name
- NCT03132792
- Testing
- Autologous genetically modified AFPᶜ³³²T cells
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 39 people
- Sponsor
- Adaptimmune
Metastatic Cancer, Congestive Heart Failure
Reducing Disparities in the Quality of Advance Care Planning for Older Adults
This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community.
- Conditions
- Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease
- Trial name
- EQUALACP (NCT03516994)
- Testing
- Respecting Choices First Steps, Five Wishes Form
- Where
- 4 sites in United States
- Volunteers
- 790 people
- Sponsor
- Duke University
Breast Neoplasms, Neoplasm Metastasis
Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC)
The investigators want to know the role of Peripheral hematopoietic stem cell infusion in avoiding Drug Induced Liver Injury,and also try to research SNPs genotyping associated with Drug Induced Liver Injury.
- Trial name
- MBC (NCT01231022)
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cancer
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
RATIONALE: PV701 may be able to kill tumor cells while leaving normal cells undamaged. PURPOSE: Phase I trial to study the effectiveness of PV701 in treating patients who have advanced or recurrent ovarian epithelial, fallopian…
- Trial name
- NCT00055705
- Testing
- PV701
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasm, Hepatocellular Carcinoma
Study of Pegylated Human Recombinant Arginase for Liver Cancer
The purpose of this study is to determine whether recombinant human arginase (PEG-BCT-100) is safe and effective in the treatment of advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT00988195
- Testing
- Pegylated Recombinant Human Arginase I, Doxorubicin
- Where
- Hong Kong
- Volunteers
- 15 people
- Sponsor
- Bio-Cancer Treatment International Limited